Pharmaceutical Kangde (603259.SH) plans to sell 100% of Kangde Hongyi and Jinshi Pharmaceutical's shares for 2.8 billion yuan

Zhitong Finance App News, Yao Ming Kangde (603259.SH) announced that Shanghai Yao Ming Kangde New Drug Development Co., Ltd. (hereinafter referred to as “Shanghai Yao Ming” or “transferee”), a wholly-owned subsidiary of the company, intends to use RMB 2.8 billion (as the benchmark share transfer price, and the final share transfer price (as defined below) will be adjusted based on the relevant agreement in the transaction agreement) to Shanghai ShiheRong Enterprise Management Consulting Co., Ltd. (hereinafter referred to as “Assignee 1”) and Shanghai ShiheMu Enterprise Management Consulting Co., Ltd. (hereinafter referred to as “Assignee 1”) and Shanghai Shihemu Enterprise Management Consulting Co., Ltd. (hereinafter referred to as “Assignee 1”) Merge with assignee 1 or less The “transferee” or “counterparty”) transferred 100% of its shares in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. (hereinafter referred to as “Kangde Hongyi” or “Target Company 1”) and Shanghai Pharmaceutical Jinshi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jinshi Pharmaceutical” or “Target Company 2”, collectively known as the “Target Company”) with the target company 1 or below.

Under this transaction, the transferee sold 100% of its shares in Target Company 1 and Target Company 2 to the transferee as an integral part of a complete transaction. After the transaction is completed, the company and its subsidiaries within the scope of the consolidated statement will no longer hold shares in the target company.

The sale of 100% of Kangde Hongyi and Jinshi Pharmaceutical's shares is based on the company's CRDMO business model, focusing on drug discovery, laboratory testing, process development, and production service considerations. It can provide financial support for the company to accelerate global capabilities and production capacity investment, and is in line with the company's development strategy and long-term interests. The target company is mainly engaged in clinical research service business. From January 2025 to September 2025, the total revenue of the target company was approximately RMB 1.16 billion (unaudited), accounting for 3.5% of the company's revenue for the first three quarters of 2025 (unaudited); from January to September 2025, the total net profit of the target company was approximately RMB 90 million (unaudited), accounting for about 0.7% of the company's net profit (unaudited) for the first three quarters of 2025.